Early Adjuvant Medication With the mTOR Inhibitor Sirolimus in a Preterm Neonate With Compressive Cystic Lymphatic Malformation

被引：9

作者：

Honnorat, Marion ^{[1
]}

Viremouneix, Loic ^{[2
,3
]}

Ayari, Sonia ^{[4
]}

Guibaud, Laurent ^{[2
,3
]}

Coste, Karen ^{[5
,6
]}

Claris, Olivier ^{[1
,7
]}

Butin, Marine ^{[1
,8
]}

机构：

[1] Hosp Civils Lyon, Serv Reanimat Neonatale, HFME, Bron, France

[2] Hosp Civils Lyon, Ctr Competence Anomalies Vasc Superficielles FAVA, HFME, Bron, France

[3] Hosp Civils Lyon, Serv Radiol Pediat, HFME, Bron, France

[4] Hosp Civils Lyon, Serv Chirurg ORL, HFME, Bron, France

[5] CHU ESTAING, Serv Reanimat Pediat & Neonatale, Clermont Ferrand, France

[6] Univ Clermont Auvergne, GReD, INSERM, CNRS,UMR 6293,U1103, Clermont Ferrand, France

[7] Univ Claude Bernard, Villeurbanne, France

[8] INSERM, Ctr Int Rech Infectiol, Equipe Pathogenese Infect Staphyloc, U1111, Lyon, France

来源：

FRONTIERS IN PEDIATRICS | 2020年 / 8卷

关键词：

lymphangioma; preterm; sirolimus; sclerotherapy; mTOR inhibitor;

D O I：

10.3389/fped.2020.00418

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Cystic lymphatic malformations result from an abnormal embryological development of the lymphatic structures. Here we report on a case of a preterm female baby, born at 34 weeks of gestation, with a voluminous cervicofacial cystic lymphatic malformation responsible for an airway obstruction. An mTOR inhibitor, sirolimus, was started from the first day of life, and was combined with iterative sclerotherapy procedures. This case illustrates a safe and successful early administration of sirolimus in a preterm neonate.

引用

页数：5

共 17 条

[11] Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3 [J].

Mäkinen, T ;

Veikkola, T ;

Mustjoki, S ;

Karpanen, T ;

Catimel, B ;

Nice, EC ;

Wise, L ;

Mercer, A ;

Kowalski, H ;

Kerjaschki, D ;

Stacker, SA ;

Achen, MG ;

Alitalo, K .

EMBO JOURNAL, 2001, 20 (17) :4762-4773

[12] Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies [J].

Mizuno, Tomoyuki ;

Fukuda, Tsuyoshi ;

Emoto, Chie ;

Mobberley-Schuman, Paula S. ;

Hammill, Adrienne M. ;

Adams, Denise M. ;

Vinks, Alexander A. .

PEDIATRIC BLOOD & CANCER, 2017, 64 (08)

[13] Oral Sirolimus: An Option in the Management of Neonates with Life-Threatening Upper Airway Lymphatic Malformations [J].

Triana, Paloma ;

Miguel, Miriam ;

Diaz, Mercedes ;

Cabrera, Marta ;

Lopez Gutierrez, Juan Carlos .

LYMPHATIC RESEARCH AND BIOLOGY, 2019, 17 (05) :504-511

[14] Sirolimus in the Treatment of Vascular Anomalies [J].

Triana, Paloma ;

Dore, Mariela ;

Nunez Cerezo, Vanesa ;

Cervantes, Manuel ;

Vilanova Sanchez, Alejandra ;

Miguel Ferrero, Miriam ;

Diaz Gonzalez, Mercedes ;

Carlos Lopez-Gutierrez, Juan .

EUROPEAN JOURNAL OF PEDIATRIC SURGERY, 2017, 27 (01) :86-90

[15] Pathogenesis of lymphangiomas [J].

Wiegand, Susanne ;

Eivazi, Behfar ;

Barth, Peter J. ;

von Rautenfeld, Dirk Berens ;

Folz, Benedikt J. ;

Mandic, Robert ;

Werner, Jochen A. .

VIRCHOWS ARCHIV, 2008, 453 (01) :1-8

[16] Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review [J].

Wiegand, Susanne ;

Wichmann, Gunnar ;

Dietz, Andreas .

LYMPHATIC RESEARCH AND BIOLOGY, 2018, 16 (04) :330-339

[17] A Case Report of 2 Sirolimus-Related Deaths Among Infants With Kaposiform Hemangioendotheliomas [J].

Ying, Hanru ;

Qiao, Congzhen ;

Yang, Xi ;

Lin, Xiaoxi .

PEDIATRICS, 2018, 141 :S425-S429

← 1 2 →